Skip to content
MarketScale
‹ Back to Industries

Sciences

What AI Means for Future Scientists

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly. History shows that technology does indeed change the nature of work. Perhaps the most dramatic example of this was the industrial revolution during the late 18th and…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Samuel Miller · AiArtificial IntelligenceAutomationHuman Jobs
Share
What AI Means for Future Scientists

Key takeaways

01

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly.

02

History shows that technology does indeed change the nature of work.

03

Perhaps the most dramatic example of this was the industrial revolution during the late 18th and…

It is a cry that has been repeated for centuries now— ‘technology will take my job.’ This is a sentiment that is certainly not to be taken lightly. History shows that technology does indeed change the nature of work. Perhaps the most dramatic example of this was the industrial revolution during the late 18th and early 19th centuries that saw Europe and America transform from agrarian states to mechanized giants powered by coal and whale oil.

A New Revolution?

Today a quieter but no less drastic shift is taking place as mobile technology, blockchain, and artificial intelligence (AI), among other digital technologies, change the nature of work for many. While a first reaction might be to worry for the safety of human jobs, it is more accurate to say that technology changes the nature of certain jobs.

For example, ATMs did not remove the job of the bank teller, it simply altered their primary role from dispensing cash, to opening accounts and other clerical tasks.

The AI Effect

Perhaps the most disruptive, and ethically vague, of these new technologies is AI. One big concern related to AI is how it will affect jobs that require advanced quantitative skills, such as those in the scientific fields. Obviously, the scientific fields encompass a great deal of jobs requiring an equally diverse set of skills and qualifications. For the purposes of this article, we are discussing jobs that require higher degree such as an MS/Ph.D, or a medical qualification such as an MD.

Beginning with the assumption that these types of jobs are more at risk of artificial intelligence automation. Jobs in scientific fields are by and large more quantitative than their counterparts in the humanities or social sciences. Quantitative work is often formulaic by nature, and therefore capable of being done by highly-intelligent computers. Certain lab processes such as component testing are already being done by machines.

However, many scientific fields also require highly specific kinds of qualitative and ethical reasoning as well. This can most easily be seen in the medical fields, where a certain amount of humanity is required to diagnose and understand medical tests.

What it Means for Science

A recent article published by a career radiologist for The Scientist magazine highlights the delicate human decisions he must make every day, decisions that, at least currently, artificial intelligence is incapable of making. He demonstrates how AI is very good at identifying the fact based “what” questions, but not the judgement based “why’s.”

These are insights based on human experience and understanding that are incredibly difficult if not impossible to program. This is the human strength of the sciences and leveraging, cultivating this advantage should become a priority for educators and institutions in the near future.

Emphasizing the human side of the sciences and making it a bigger part of the field, will help prevent AI from automating science field jobs. And it is not just the sciences; Re-discovering the humanities has been a growing movement in areas such as business as well, where fields like ethical philosophy and creative design thinking have become popular to not just avoid automation, but to inject some meaning and, well, humanity into the field. At the end of the day, machines are not human and, at least for now, there are somethings that humans are just better at.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

SM
Samuel Miller

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SM
Samuel Miller